ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

A growing body of evidence suggests that aggregated α-synuclein, the major constituent of Lewy bodies, plays a key role in the pathogenesis of Parkinson's disease and related α-synucleinopathies. Immunotherapies, both active and passive, against α-synuclein have been developed and are promising...

Full description

Bibliographic Details
Main Authors: Eva Nordström, Fredrik Eriksson, Jessica Sigvardson, Malin Johannesson, Alex Kasrayan, Martina Jones-Kostalla, Paulina Appelkvist, Linda Söderberg, Patrik Nygren, Magdalena Blom, Adeline Rachalski, Karin Nordenankar, Olof Zachrisson, Ebba Amandius, Gunilla Osswald, Mikael Moge, Martin Ingelsson, Joakim Bergström, Lars Lannfelt, Christer Möller, Marco Giorgetti, Johanna Fälting
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Neurobiology of Disease
Subjects:
Parkinson's disease
α-Synuclein
Humanized monoclonal antibody
Immunotherapy
Clinical development
ABBV-0805
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996121002928

Internet

http://www.sciencedirect.com/science/article/pii/S0969996121002928

Similar Items